

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM580848

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Clovis Oncology, Inc.		03/11/2019	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Celgene CAR LLC		
Street Address:	30 Woodbourne Avenue, AON House		
City:	Pembroke		
State/Country:	BERMUDA		
Postal Code:	HM08		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87731989	XEGAFRI	
CORRESPONDENCE DATA			
Fax Number:	2157012273		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2156657273		
Email:	cmiller@cozen.com		
Correspondent Name:	Camille M. Miller		
Address Line 1:	1650 Market Street		
Address Line 2:	Suite 2800		
Address Line 4:	Philadelphia, PENNSYLVANIA 19103		
ATTORNEY DOCKET NUMBER:	CELG1963US2/451735		
NAME OF SUBMITTER:	Camille M. Miller		
SIGNATURE:	/Camille M. Miller/		
DATE SIGNED:	06/11/2020		
Total Attachments: 2			
source=Celgene CAR Ltd LLC - Trademark Assign. - Signed KM#page1.tif			
source=Celgene CAR Ltd LLC - Trademark Assign. - Signed KM#page2.tif			

OP \$40.00 87731989

TRADEMARK ASSIGNMENT


WHEREAS, CLOVIS ONCOLOGY, INC., a Delaware corporation, located at 5500 Flatiron Parkway, Suite 100, Boulder, CO 80303, was the owner of the XEGAFRI Trademark Registrations and Applications listed in Exhibit A (hereinafter referred to as "Trademarks"); and

WHEREAS, CELGENE CAR LLC, a Delaware limited liability company, located at AON House, 30 Woodbourne Avenue, Pembroke, Bermuda HM 08, did acquire as of March 6, 2019 all right title and interest in and to the Trademarks, and the goodwill of the business relating thereto.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, CLOVIS ONCOLOGY, INC. hereby sells, assigns, transfers and conveys to CELGENE CAR LLC all right, title, and interest in and to the Trademarks, all choses in action (including the right to bring suit for past infringement of the Trademarks), the right to file applications for and secure registrations thereof and to renew, extend, maintain, abandon or otherwise control any Trademarks and associated applications, registrations and renewals, reissues, and extensions thereof in the United States of America or any other country, together with the goodwill of the business symbolized by the Trademarks, and any applications and registrations therefor, the same to be held and enjoyed by CELGENE CAR LLC, its successors and assigns, from and after the date hereof as fully and entirely as the same would have been held and enjoyed by CLOVIS ONCOLOGY, INC. had this Assignment not been made, and all common law rights in the Trademarks.

WHEREAS, it is desired that this Assignment be made of record in the U.S. Patent and Trademark Office and all other applicable trademark offices throughout the world.


Assignor: CLOVIS ONCOLOGY, INC

Name: 
Title: EVP, General Counsel

March 11, 2019


Assignee: CELGENE CAR LLC

CELGENE CAR LLC
By its sole member Celgene CAR Ltd.

By: 
Kevin Mello, Director

March 11, 2019

CELGENE CAR LTD.

By: 
Kevin Mello, Director

March 11, 2019

Exhibit A

MARK	CTR Y	APP#	FILED	REG#	STATUS	CLASS	GOODS/SERVICES
XEGAFRI	AE	230583	Apr 8, 2015	230583	Registered	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	AR	3375505	Dec 18, 2014	2770039	Registered	05	Entire class; specifically, pharmaceutical products for the treatment of cancer
XEGAFRI	BR	908800800	Dec 22, 2014	908800800	Registered	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	CA	1708586	Dec 15, 2014		Allowed	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	HK	303238173	Dec 16, 2014	303238173	Registered	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	ID	D00201405981 6	Dec 24, 2014	IDM000582 956	Pending	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	IN	2863577	Dec 16, 2014	2863577	Registered	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	MY	2014069261	Dec 19, 2014	2014069261	Registered	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	US	87731989	Dec 22, 2017		Allowed	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	SA	1436008784	Feb 12, 2015	1436008784	Registered	05	Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides
XEGAFRI	TH	966908	Dec 19, 2014	161113701	Registered	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	TW	103072878	Dec 18, 2014	1719475	Registered	05	Pharmaceutical products for the treatment of cancer
XEGAFRI	ZA	201434624	Dec 18, 2014	201434624	Registered	05	Pharmaceutical products for the treatment of cancer

TRADEMARK